Sign In
Buy EFTR
$0.0006
+0 (+0%)
At Close: Jun 03, 2026
eFFECTOR Therapeutics to Present at 2022 BIO CEO & Investor Conference
04:00pm, Wednesday, 09'th Feb 2022
SAN DIEGO and REDWOOD CITY, Calif., Feb. 09, 2022 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics (NASDAQ: EFTR), a biopharmaceutical company focused on pioneering the development of selective translation r
eFFECTOR Therapeutics to Participate in Upcoming Investor Conferences
08:00am, Tuesday, 26'th Oct 2021
SAN DIEGO, Oct. 26, 2021 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today
EFTR Stock: Why It Increased By 25% Today
11:16am, Friday, 08'th Oct 2021
The stock price of eFFECTOR Therapeutics (NASDAQ: EFTR) increased by 25% during intraday trading. This is why it happened.
eFFECTOR Therapeutics Stock Gains On Encouraging Preclinical Zotatifin Data In Breast Cancer
07:34am, Friday, 08'th Oct 2021
eFFECTOR Therapeutics Inc (NASDAQ: EFTR), in collaboration with Baylor College of Medicine, announced the presentation of new positive data for zotatifin in animal models of triple-negative breast
• Demonstrated statistically significant anti-tumor activity and inhibited proliferative and stem-cell signaling pathways
SAN DIEGO, Sept. 30, 2021 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today
Hold Off on eFFECTOR Therapeutics if You Can't Stomach the Risk
04:32pm, Tuesday, 28'th Sep 2021
While EFTR stock has escaped the usual underperformance of SPAC IPOs so far, eFFECTOR Therapeutics still remains a risky proposition. The post Hold Off on eFFECTOR Therapeutics if You Can't Stomach th
eFFECTOR Therapeutics Stock Might Be Worth the Risk in Small Quantities
06:00am, Monday, 20'th Sep 2021
During the post-SPAC spectacle, EFTR stock be volatile - this should be expected. Still, eFFECTOR's oncology therapies look promising.
eFFECTOR Therapeutics to Participate in 2021 Cantor Virtual Healthcare Conference
08:00am, Thursday, 16'th Sep 2021
SAN DIEGO, Sept. 16, 2021 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today
What's Going On With eFFECTOR Therapeutics Stock Today?
02:54pm, Monday, 13'th Sep 2021
eFFECTOR Therapeutics Inc (NASDAQ: EFTR) is trading higher Monday after Cantor Fitzgerald initiated coverage on the stock. Cantor Fitzgerald analyst Louise Chen initiated coverage on eFFECTOR Therap
eFFECTOR: Developing New Class Of Cancer Therapies
06:48am, Sunday, 12'th Sep 2021
eFFECTOR Therapeutics is pioneering the development of a new class of oncology drugs known as STRIs. The STRI therapy is also being evaluated for COVID-19 at UCSF under a DARPA grant.
Why eFFECTOR Therapeutics Stock Is Heating Up Today
11:49am, Thursday, 09'th Sep 2021
The biotech's novel cancer platform is fueling buyout speculation on social media today.
EFTR Stock: 7 Things to Know About eFFECTOR as Shares Shoot Up 100%
01:51pm, Wednesday, 08'th Sep 2021
Here's what investors may want to know about eFFECTOR and EFTR stock, as the company's shares surge once again today in a big way. The post EFTR Stock: 7 Things to Know About eFFECTOR as Shares Shoot
EFTR Stock: What Is Going on With Red-Hot eFFECTOR Therapeutics Today?
05:42pm, Tuesday, 07'th Sep 2021
After a tough week for SPACs, EFTR stock has enjoyed significant gains today. The SPAC bubble may not be over yet.
Common stock and warrants expected to commence trading on Nasdaq on August 26, 2021 under the ticker symbols EFTR and EFTRW Common stock and warrants expected to commence trading on Nasdaq on August 2
